<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002389</url>
  </required_header>
  <id_info>
    <org_study_id>238D</org_study_id>
    <nct_id>NCT00002389</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination With Lamivudine (3TC) and Zidovudine (ZDV) Versus 3TC/ZDV in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects With CD4+ Counts &gt;= 100 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the durability of the viral load response following 48 weeks of treatment with&#xD;
      1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone. To compare the early&#xD;
      antiviral activity following 16 weeks treatment with 1592U89/3TC/ZDV versus 3TC/ZDV alone as&#xD;
      demonstrated by the proportion of subjects with viral load &lt; 400 copies/ml, plasma HIV-1 RNA&#xD;
      profiles and CD4+ profiles. To assess the safety and tolerance following 16 and 48 weeks of&#xD;
      treatment with 1592U89/3TC/ZDV versus 3TC/ZDV alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares the safety and efficacy of 1592U89 in combination with 3TC and ZDV versus&#xD;
      control therapy with 3TC and ZDV alone. If a patient has two consecutive HIV-1 RNA&#xD;
      measurements of &gt;= 400 copies/ml (performed at least one week apart) he or she has the option&#xD;
      to switch to open-label therapy with 1592U89/3TC/ZDV, to receive the remaining randomized&#xD;
      treatment, or to discontinue study medication. If this criterion is not met, patients&#xD;
      continue their randomly assigned therapy until the last patient has completed 48 weeks of&#xD;
      therapy. Once patients enter the open-label phase, investigators may add or substitute&#xD;
      non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors,&#xD;
      or protease inhibitors for 3TC and/or ZDV according to their standard practice once patients&#xD;
      enter the open-label phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>210</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Local treatment for Kaposi's sarcoma.&#xD;
&#xD;
          -  Hematologic supportive therapy with GM-CSF, G-CSF, or erythropoietin.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-1 infection as documented by a licensed HIV-1 antibody ELISA and confirmed by&#xD;
             either Western blot detection of HIV-1 antibody or positive HIV-1 blood culture.&#xD;
&#xD;
          -  One screening CD4 lymphocyte cell count &gt;= 100 cells/mm3 within 14 days prior to study&#xD;
             drug administration.&#xD;
&#xD;
          -  No active or ongoing AIDS-defining opportunistic infection or disease.&#xD;
&#xD;
          -  Signed, informed consent from parent or legal guardian for patients under 18 years of&#xD;
             age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions and symptoms are excluded:&#xD;
&#xD;
          -  Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with&#xD;
             drug absorption or render the patient unable to take oral medication.&#xD;
&#xD;
          -  Serious medical conditions such as diabetes, congestive heart failure, cardiomyopathy,&#xD;
             or other cardiac dysfunction, that, in the opinion of the investigator, would&#xD;
             compromise the safety of the patient.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Foscarnet therapy.&#xD;
&#xD;
          -  Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide,&#xD;
             anti-cytokine agents, or interferons.&#xD;
&#xD;
          -  Cytotoxic chemotherapeutic agents and antioxidants.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of clinically relevant pancreatitis or hepatitis within the last 6 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior antiretroviral therapy.&#xD;
&#xD;
          -  Vaccination within the past 3 months given as part of an investigational HIV vaccine&#xD;
             trial.&#xD;
&#xD;
          -  Chemotherapeutic agents within 30 days of study drug administration.&#xD;
&#xD;
          -  Immunomodulating agents such as systemic corticosteroids, interleukins or interferons,&#xD;
             within 30 days of study drug administration.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy within 30 days of study period. Current alcohol or illicit drug use that,&#xD;
        in the opinion of the investigator, may interfere with the patient's ability to comply with&#xD;
        the dosing schedule and protocol evaluations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>East Bay AIDS Ctr</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kraus Med Partners</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami Dept of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Med College / Rush Presbyterian - St Luke's Med Cen</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Med Ctr / Evans - 556</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021182393</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Med Ctr / Dept of Infectious Diseases</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hosp and Med Ctr / AIDS Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr / Dept of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati / Holmes Hosp</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Nicholaos Bellos</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine / Dept of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>770303498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Gen Hosp</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan AIDS Program</name>
      <address>
        <city>Santurce</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <keyword>abacavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

